Jiangxi Pingxiang People's Hospital
Pingxiang, Jiangxi 337055
1 studies enrolling now · 12 studies all time
What they study most
Arthritis, Atrial Fibrillation, Autoimmune Diseases, Brain Edema, Chronic Obstructive Pulmonary Disease, Connective Tissue Diseases, Heart Failure With Preserved Ejection Fraction (HFpEF), Immune System Diseases, Joint Diseases, Lupus Erythematosus, Systemic, Musculoskeletal Diseases, Non-diabetic Chronic Kidney Disease
Studies at this site
- A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) — Recruiting now
- A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes — Completed
- A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis — Completed
- A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease — Completed
- A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus — Running, not enrolling
- A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis — Stopped early
- A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin — Completed
- A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial — Completed
- An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) — Completed
- A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke — Stopped early
- Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction — Stopped early
- A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus — Stopped early